Table of Contents
If you need this cutting-edge cancer cure, don't live in India.
That was the sad reality Indian cancer patients faced just a few years ago when trying to access CAR-T therapy.
But now, thanks to ImmunoACT, those patients are being cured with India’s first homegrown CAR-T —NexCAR19.
CAR-T ranks among the most powerful cancer treatments in the world, curing cancers that were considered virtually untreatable. ImmunoACT believes that all of us deserve affordable access to CAR-T therapy, no matter the country we live in.
In this video I produced with Onyx, I tell the story of how this Indian biotech startup slashed the cost of CAR-T from $475,000 to just $30,000 and started a revolution in global CAR-T therapy access.
I hope you enjoy watching it as much as I enjoyed making it. Thanks to the ImmunoACT team for their input, especially Rahul Purwar and Sushant Kumar.
Coming up: Cell & Gene Leaders Live, Sun 15 Nov at The Shard · London Life Sciences Week Guide, 15–19 Nov 2026 ·
Comments